Bayer shares jump after creating a separate U.S. entity for its Roundup business, fueling speculation over a potential breakup.
Bayer’s stock climbed 9% in European trading Thursday, reaching its highest level in nearly three years. The rally followed the company’s announcement to consolidate its U.S. Roundup business into a new standalone entity, a move seen as a step toward a potential corporate breakup.
The decision comes a week after the U.S. Supreme Court declined to review a key Roundup litigation case, reducing legal uncertainty. Analysts at Deutsche Bank upgraded Bayer to Buy, citing improved clarity on liability risks and restructuring potential.
The stock’s surge reflects investor optimism about Bayer’s ability to streamline operations and unlock value amid ongoing legal and operational challenges.